Advancements and Challenges in Antiamyloid Therapy for Alzheimer’s Disease: A Comprehensive Review
International Journal of Alzheimer’s Disease · 2024-01 · 2024 (1)
DOI: 10.1155/2024/2052142 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Alzheimer’s Disease, online erschienen am 22.07.2024. Verfasst von Semira Abdi Beshir und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice Dubai Pharmacy College for Girls, Dubai, UAE. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder caused by the accumulation of amyloid‐beta (A β ) proteins and neurofibrillary tangles in the brain. There have been recent advancements in antiamyloid therapy for AD. This narrative review explores the recent advancements and challenges in antiamyloid therapy. In addition, a summary of evidence from antiamyloid therapy trials is presented with a focus on lecanemab. Lecanemab is the most recently approved monoclonal antibody that targets A β protofibrils for the treatment of patients with early AD and mild cognitive impairment (MCI). Lecanemab was the first drug shown to slow cognitive decline in patients with MCI or early onset AD dementia when administered as an infusion once every two weeks. In the Clarity AD trial, lecanemab was associated with infusion‐site reactions (26.4%) and amyloid‐related imaging abnormalities (12.6%). The clinical relevance and long‐term side effects of lecanemab require further longitudinal observation. However, several challenges must be addressed before the drug can be routinely used in clinical practice. The drug’s route of administration, need for imaging and genetic testing, affordability, accessibility, infrastructure, and potential for serious side effects are some of these challenges. Lecanemab’s approval has fueled interest in the potential of other antiamyloid therapies, such as donanemab. Future research must focus on developing strategies to prevent AD; identify easy‐to‐use validated plasma‐based assays; and discover newer user‐friendly, and cost‐effective drugs that target multiple pathways in AD pathology.
Autor:innen und Institutionen
- Department of Pharmacy Practice Dubai Pharmacy College for Girls, Dubai, UAE.
- Department of Pharmaceutical Sciences College of Pharmacy Al Ain University, Al Ain, UAE.
- AAU Health and Biomedical Research Centre Al Ain University, Abu Dhabi, UAE.
- Department of Pharmacy Practice College of Pharmacy Gulf Medical University, Ajman, UAE.
- Chief Operations Office Sheikh Shakhbout Medical City (SSMC) PureHealth, Abu Dhabi, UAE.
- Dubai Pharmacy College for Girls, Dubai, UAE.
ORCID-Profile: Semira Abdi Beshir, Nadia Hussain, Vineetha Bharathan Menon, Amal H I Al Haddad, Rahaf Adnan Kh Al Zeer, Asim Ahmed Elnour
Zitieren
APA
Beshir, S. A., Hussain, N., Menon, V. B., Al Haddad, A. H. I., Al Zeer, R. A. K., & Elnour, A. A. (2024). Advancements and Challenges in Antiamyloid Therapy for Alzheimer’s Disease: A Comprehensive Review. International Journal of Alzheimer’s Disease, 2024(1). https://doi.org/10.1155/2024/2052142
Vancouver
Beshir SA, Hussain N, Menon VB, Al Haddad AHI, Al Zeer RAK, Elnour AA. Advancements and Challenges in Antiamyloid Therapy for Alzheimer’s Disease: A Comprehensive Review. International Journal of Alzheimer’s Disease. 2024;2024(1). doi:10.1155/2024/2052142
BibTeX
@article{Beshir2024,
author = {Beshir, Semira Abdi and Hussain, Nadia and Menon, Vineetha Bharathan and Al Haddad, Amal H I and Al Zeer, Rahaf Adnan Kh and Elnour, Asim Ahmed},
title = {Advancements and Challenges in Antiamyloid Therapy for Alzheimer’s Disease: A Comprehensive Review},
journal = {International Journal of Alzheimer’s Disease},
year = {2024},
volume = {2024},
number = {1},
doi = {10.1155/2024/2052142}
}
EUVIMED